Fig. 5.
Kaplan-Meier survival analysis (log-rank test) for the patient cohort with TP53 wild-type EACs and ARID1a proficient versus deficient expression. Significant survival differences between patients with TP53 non-mutated (wild-type) EACs and ARID1a expression (median overall-survival 60.1 months (95% confidence interval (95%CI) 1.2–139.9 months) compared to TP53 wild-type EACs showing an ARID1a loss (median overall-survival 26.2 months (95%CI 3.7–19.1 months), p = 0.044)